Microbiology & Immunology of the Chronically-inflamed Airway

Status Completed

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death and the only one of the common causes that is still rising. The main effects of the disease are the destruction and inflammation of lung tissue rendering breathing difficult. COPD has significant effects on the quality of life of sufferers and the disease is predicted to be the fifth most common cause of disability in the world by 2020. Patients with COPD are prone to periods of worsening disease symptoms, known as exacerbations, which are often caused by viral and bacterial infections of the lung and current vaccines appear to have little efficacy in limiting these exacerbations. The loss of lung function caused by infectious exacerbations is irreversible and patients who frequently exacerbate experience more rapid disease progression. Nontypeable Haemophilus influenzae (NTHi) is a major bacterial species that colonises the airways and causes exacerbations in COPD. With the development of more sensitive molecular techniques it has been possible to ascertain that it is the acquisition of new strains of NTHi that correlate strongly with exacerbations. However, not all patients with COPD have NTHi in their lungs and the question remains as to why some COPD patients are susceptible to such infections. This study aims to answer this question by comparing the airways of COPD patients who are colonized by NTHi and those who are not to analyse whether the levels of protective antibodies in the lungs and the function of the immune cells in the NTHi colonized airway are reduced. Moreover, we aim to correlate this reduction in immunity with areas of lung damage ascertained by high resolution computed tomography. The aim of this research is to better understand this apparent deficiency in airway immunity as this is likely to impact on vaccine efficacy in COPD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease (COPD)
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT01701869
Study type	Observational
Source	University Hospital Southampton NHS Foundation Trust
Contact
Status	Completed
Phase	N/A
Start date	September 2012
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03282019` - Study of Long-term HFNC for COPD Patients With HOT	N/A
Completed	`NCT05573464` - A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 3
Recruiting	`NCT06040086` - Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations	Phase 3
Not yet recruiting	`NCT06376994` - Multi-Center Clean Air Randomized Controlled Trial in COPD	Phase 3
Completed	`NCT02728674` - Management of Patients With Respiratory Symptoms in Sweden	N/A
Completed	`NCT02797392` - Feasibility of a Preventive Program Against Lifestyle Related Diseases	N/A
Completed	`NCT02926534` - Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan	N/A
Recruiting	`NCT02415478` - Bronchioscopic Lung Volume Reduction (BLVR)	N/A
Completed	`NCT02512510` - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT02518139` - A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT02459080` - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT02774226` - Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease	Phase 2
Completed	`NCT03487406` - Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)	Phase 2
Completed	`NCT01908140` - Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Withdrawn	`NCT01908933` - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema	Phase 3
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01893476` - A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management	N/A
Recruiting	`NCT02527486` - Seoul National University Airway Registry	N/A
Terminated	`NCT01388920` - Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting	Phase 2
Withdrawn	`NCT01377428` - Efficacy of Indacaterol 150 µg Versus Formoterol	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Microbiology & Immunology of the Chronically-inflamed Airway — MICA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms